Items where Author is "Smyth, Alan R"
Up a level |
Group by: Item Type | No Grouping
Number of items: 2.
Marsh, Ryan ORCID: https://orcid.org/0000-0002-3790-1721, Dos Santos, Claudio ORCID: https://orcid.org/0000-0003-0144-4327, Yule, Alexander ORCID: https://orcid.org/0000-0002-2666-2673, Dellschaft, Neele S ORCID: https://orcid.org/0000-0001-5483-1684, Hoad, Caroline L ORCID: https://orcid.org/0000-0001-5483-1027, Ng, Christabella ORCID: https://orcid.org/0000-0001-7243-3014, Major, Giles ORCID: https://orcid.org/0000-0001-7944-3709, Smyth, Alan R ORCID: https://orcid.org/0000-0001-5494-5438, Rivett, Damian ORCID: https://orcid.org/0000-0002-1852-6137 and van der Gast, Christopher ORCID: https://orcid.org/0000-0003-1101-4048
(2024)
Impact of extended Elexacaftor/Tezacaftor/Ivacaftor therapy on the gut microbiome in cystic fibrosis.
Journal of Cystic Fibrosis, 23 (5).
pp. 967-976.
ISSN 1569-1993
Marsh, Ryan, Dos Santos, Claudio, Hanson, Liam, Ng, Christabella, Major, Giles, Smyth, Alan R, Rivett, Damian ORCID: https://orcid.org/0000-0002-1852-6137 and van der Gast, Christopher ORCID: https://orcid.org/0000-0003-1101-4048
(2023)
Tezacaftor/Ivacaftor therapy has negligible effects on the cystic fibrosis gut microbiome.
Microbiology Spectrum, 11 (5).
ISSN 2165-0497